C4 Therapeutics, Inc. (CCCC) Free cash flow 2019–2025
C4 Therapeutics, Inc. (CCCC) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$99.3MFY2025 · since FY2019: $54.3M → -$99.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$99.3M | -52.0% |
| FY2024 | -$65.3M | +39.8% |
| FY2023 | -$108.5M | +2.6% |
| FY2022 | -$111.4M | -26.3% |
| FY2021 | -$88.2M | -30.0% |
| FY2020 | -$67.9M | -225.1% |
| FY2019 | $54.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CCCC financial trends
CCCC RevenueCCCC Net incomeCCCC Net marginCCCC Gross profitCCCC Gross marginCCCC Operating incomeCCCC Operating marginCCCC Operating cash flowCCCC Capital expendituresCCCC Return on equityCCCC Stock buybacksCCCC Dividends paidCCCC Total assetsCCCC Total liabilitiesCCCC Shareholders’ equityCCCC overview →